MedTrace Logo

EXOMIND (BTL-699-2) for Improvement of Mental Well-being

NCT06899646 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-07-21

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate if the treatment with EXOMIND (BTL-699-2) device is able to improve mental well-being in adults above the age of 22 years. The main question it aims to answer is:

Does the treatment with EXOMIND (BTL-699-2) device improve mental well-being?

Participants will be asked to:

* Undergo four treatments
* Complete the Warwick Edinburgh Mental Well-being Scale
* Complete the Therapy Comfort Questionnaire
* Complete the Subject Satisfaction \& Mental Wellness Questionnaire

Conditions

  • Well-Being, Psychological

Interventions

DEVICE

Treatment with BTL-699-2

Four transcranial magnetic stimulation treatments with the BTL-699-2 device will be delivered over the left dorsolateral prefrontal cortex, spaced 5 to 10 days apart. The intensity will be adjusted according to the subject's feedback, up to 100% of the individual's motor threshold.

Sponsors & Collaborators

  • BTL Industries Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-08
Primary Completion
2025-02-03
Completion
2025-02-03
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06899646 on ClinicalTrials.gov